Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.RedHill Biopharma starts phase II study of Bekinda for irritable bowel syndrome
The double-blind, two-arm parallel group study will randomize 120 patients to receive 12 mg of Bekinda or placebo once daily for eight weeks. The primary endpoint is the
The double-blind, two-arm parallel group study will randomize 120 patients to receive 12 mg of Bekinda or placebo once daily for eight weeks. The primary endpoint is the
Venclexta is being developed by AbbVie and Genentech. It is the first therapy approved by the FDA, targeting the the B-cell lymphoma 2 (BCL-2) protein which supports cancer
The approval was based on data from the SENSE clinical study, which evaluate the safety and immunogenicity of HX575 epoetin alfa in the treatment of anemia associated with
ANAVEX 3-71 is a preclinical drug candidate with a novel mechanism of action through sigma-1 receptor activation and M1 muscarinic allosteric modulation, which has demonstrated to enhance neuroprotection
The companies formed an alliance in 2014 to develop and commercialize AZD3293, an oral beta secretase cleaving enzyme (BACE) inhibitor. The new milestone means Eli Lilly will pay
The target date for the FDA to take action under the Prescription Drug User Fee Act is 29 May. If approved by FDA, the drug would be the
The approval expands treatment options for pediatric patients aged 1 year and above with chronic ITP who have not responded to other therapies. Two formulations have been approved
Janssen Biotech will develop and commercialize Tesaro’s Niraparib for treatment of prostate cancer. Niraparib, formerly known as MK-4827, is an orally active and potent poly (ADP-ribose) polymerase, or
Under the deal, Allergan will pay $125m upfront to Heptares for exclusive global rights to a portfolio of treatments for neurological disorders. Heptares is also eligible for milestone
The drug is already approved in Europe for use in previously treated patients with metastatic squamous NSCLC. Opdivo’s indication has now been expanded to include non-squamous NSCLC, which